Lipodystrophy in HIV-1-infected patients (multiple letters) [5]

Lancet

Volumn 354, Issue 9181, 1999, Pages 867-868

  Mercie, P ^a   Tchamgoue, S ^a   Dabis, F ^a   Pellegrin, J L ^a   Domingo, P ^a   Perez, A ^a   Torres, O H ^a   Montiel, J A ^a   Vazquez, G ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

CARDIOVASCULAR RISK; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; SCREENING; VIRUS LOAD; ADULT; CHEMICALLY INDUCED DISORDER; NOTE;

ADULT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPODYSTROPHY; MALE;

EID: 0033523350     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)75937-7     Document Type: Letter

References (1)

1. A Carr K Samaras A Thorisdottir GR Kaufmann DJ Chisholm DA Cooper Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 353 1999 2093 2099